Adma Biologics Inc (NASDAQ: ADMA) kicked off on Monday, down -11.15% from the previous trading day, before settling in for the closing price of $18.56. Over the past 52 weeks, ADMA has traded in a range of $4.77-$23.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 73.38%. While this was happening, its average annual earnings per share was recorded 498.08%. With a float of $228.50 million, this company’s outstanding shares have now reached $236.38 million.
Let’s determine the extent of company efficiency that accounts for 624 employees. In terms of profitability, gross margin is 48.79%, operating margin of 30.01%, and the pretax margin is 19.16%.
Adma Biologics Inc (ADMA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Adma Biologics Inc is 3.34%, while institutional ownership is 88.45%. The most recent insider transaction that took place on Nov 22 ’24, was worth 317,250. In this transaction CFO and Treasurer of this company sold 15,000 shares at a rate of $21.15, taking the stock ownership to the 199,433 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO sold 48,967 for $21.10, making the entire transaction worth $1,033,204. This insider now owns 1,989,007 shares in total.
Adma Biologics Inc (ADMA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 498.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.00% during the next five years compared to 38.68% growth over the previous five years of trading.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Take a look at Adma Biologics Inc’s (ADMA) current performance indicators. Last quarter, stock had a quick ratio of 3.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.18. Likewise, its price to free cash flow for the trailing twelve months is 49.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.28, a number that is poised to hit 0.16 in the next quarter and is forecasted to reach 0.73 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Looking closely at Adma Biologics Inc (NASDAQ: ADMA), its last 5-days average volume was 2.64 million, which is a jump from its year-to-date volume of 2.49 million. As of the previous 9 days, the stock’s Stochastic %D was 46.91%. Additionally, its Average True Range was 0.94.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 13.96%, which indicates a significant increase from 0.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.42% in the past 14 days, which was lower than the 67.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.28, while its 200-day Moving Average is $14.34. However, in the short run, Adma Biologics Inc’s stock first resistance to watch stands at $17.64. Second resistance stands at $18.78. The third major resistance level sits at $19.37. If the price goes on to break the first support level at $15.91, it is likely to go to the next support level at $15.32. Now, if the price goes above the second support level, the third support stands at $14.18.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
The company with the Market Capitalisation of 3.90 billion has total of 236,390K Shares Outstanding. Its annual sales at the moment are 258,220 K in contrast with the sum of -28,240 K annual income. Company’s last quarter sales were recorded 119,840 K and last quarter income was 35,910 K.
